Connect Biopharma (CNTB) vs Fractyl Health (GUTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Connect Biopharma (CNTB) has outperformed Fractyl Health (GUTS) over the past year, losing 51.6% versus a loss of 74.8%. Fractyl Health is the larger company by market cap ($56.1 million vs $55.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTB | GUTS |
|---|---|---|
| Share price | $0.8807 | $4.23 |
| Market cap | $55.46M | $56.11M |
| 1-day change | -6.77% | -6.42% |
| YTD return | -68.77% | -83.98% |
| 1-year return | -51.61% | -74.82% |
| 5-year return | -94.87% | — |
| EPS (TTM) | $-1.19 | $-10.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.82 | $29.34 |
| 52-week low | $0.85 | $4.14 |
| Distance from 52-week high | -76.95% | -85.58% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +567.65% | +1327.90% |
| Average volume | 3.81M | 152.04K |
| Shares outstanding | 62.97M | 13.26M |
| Employees | 64 | 100 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CNTB has outperformed GUTS by 23.2 percentage points over the past year.
About Connect Biopharma
CNTB stock →Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).
Healthcare · Biotechnology · 64 employees
About Fractyl Health
GUTS stock →Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Healthcare · Biotechnology · 100 employees
CNTB vs GUTS FAQ
Which is bigger, Connect Biopharma or Fractyl Health?
Fractyl Health (GUTS) is larger, with a market capitalization of $56.11M compared with $55.46M for Connect Biopharma (CNTB).
Which stock has performed better over the past year, CNTB or GUTS?
CNTB returned -51.61% over the past 12 months, compared with -74.82% for GUTS (price return, excluding dividends). Past performance does not predict future results.
Are Connect Biopharma and Fractyl Health in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.